These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Antiviral therapy for HCV recurrence after liver transplantation is a challenging issue. How do we manage treatment?

Antiviral Treatment for HCV Recurrence After Liver Transplantation When, How Much and for How Long?

In other recent news, AbbVie has received FDA approval for MAVYRET as the first oral treatment for acute hepatitis C, expanding its use to include adults and children aged three and older. The ...

MAVYRET continues to feature prominently in AbbVie's liver disease segment. Label expansion may lead to broader clinical adoption, especially for patients with specific treatment criteria.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

In other recent news, AbbVie received FDA approval for MAVYRET, now the first oral treatment for acute hepatitis C, expanding its use to both adults and children. This approval follows a Phase 3 study ...